Siloxane-based artificial blockage to control bleeding

A two-fluid component injection device for in situ formation of a soft solid artificial blockage to control moderate to severe bleeding, the two-fluid component injection device comprising two isolated chambers, wherein the two isolated chambers comprise a first isolated chamber and a second isolated chamber, the two-fluid component injection device comprising:

• a) the first isolated chamber comprising a first fluid component, the first fluid component comprising:
• i) about 84% by weight or volume of at least one siloxane polymer;
• ii) about 0.5-2% by weight or volume of at least one surfactant;
• iii) about 0.5-3% by weight or volume of at least one siloxane polymer curing agent;
• and
• iv) about 12-18% by weight or volume of a metal mixture selected from the group consisting of 1) calcium oxide and iron oxides, and, 2) calcium hydroxide and iron oxides;
• b) the second isolated chamber comprising a second fluid component, the second fluid component comprising:
• i) about 82% by weight or volume of at least one siloxane polymer;
• ii) about 0.5-2% by weight or volume of at least one surfactant;
• iii) about 17.5% by weight or volume of hydrogen peroxide;
• and
• iv) about 0.2% by weight or volume of at least one particle filler.

A soft solid hemostatic blockage composition formed in situ by using a two-fluid component injection device to control moderate to severe bleeding, the two-fluid component injection device comprising two isolated chambers, wherein the two isolated chambers comprise a first isolated chamber and a second isolated chamber, the two-fluid component injection device comprising:

• a) the first isolated chamber comprising a first fluid component, the first fluid component comprising:
• i) about 75-90% by weight or volume of at least one siloxane polymer;
• ii) about 0-25% by weight or volume of at least one surfactant;
• iii) about 0.5-25% by weight or volume of at least one siloxane polymer curing agent;
• and
• iv) about 12-18% by weight or volume of a metal mixture selected from the group consisting of 1) calcium oxide and iron oxides, and, 2) calcium hydroxide and iron oxides;
• b) the second isolated chamber comprising a second fluid component, the second fluid component comprising:
• i) about 75-85% by weight or volume of at least one siloxane polymer;
• ii) about 0-25% by weight or volume of at least one surfactant;
• iii) about 1-20% by weight or volume of hydrogen peroxide;
• and
• iv) about 0-10% by weight or volume of at least one particle filler, wherein the soft solid hemostatic blockage composition conforms to irregular wound surfaces.

A soft solid hemostatic blockage composition formed in situ by using a two-fluid component injection device to control moderate to severe bleeding, the two-component injection device comprising two isolated chambers, wherein the two isolated chambers comprise a first isolated chamber and a second isolated chamber, the two-fluid component injection device comprising:

• a) the first isolated chamber comprising a first fluid component, the first fluid component comprising:
• i) about 84% by weight or volume of at least one siloxane polymer;
• ii) about 0.5-2% by weight or volume of at least one surfactant;
• iii) about 0.5-3% by weight or volume of at least one siloxane polymer curing agent;
• and
• iv) about 12-18% by weight or volume of a metal mixture selected from the group consisting of 1) calcium oxide and iron oxides, and, 2) calcium hydroxide and iron oxides;
• b) the second isolated chamber comprising a second fluid component, the second fluid component comprising:
• i) about 82% by weight or volume of at least one siloxane polymer;
• ii) about 0.5-2% by weight or volume of at least one surfactant;
• iii) about 17.5% by weight or volume of hydrogen peroxide;
• and
• iv) about 0.2% by weight or volume of at least one particle filler, wherein the soft solid hemostatic blockage composition conforms to irregular wound surfaces.

A method for in situ formation of a soft solid artificial blockage in a wound or body cavity to control moderate to severe bleeding, comprising injecting from a two-fluid component injection device into the wound or body cavity, a composition that forms a soft solid artificial blockage within the wound, the two-fluid component injection device comprising two isolated chambers, wherein the two isolated chambers comprise a first isolated chamber and a second isolated chamber, the two-fluid component injection device comprising:

• a) the first isolated chamber comprising a first fluid component, the first fluid component comprising:
• i) about 75-90% by weight or volume of at least one siloxane polymer;
• ii) about 0.5-25% by weight or volume of at least one siloxane polymer curing agent;
• iii) about 12-18% by weight or volume of a metal mixture selected from the group consisting of 1) calcium oxide and iron oxides, 2) calcium hydroxide and iron oxides;
• and,
• iv) about 0-25% of a surfactant;
• b) the second isolated chamber comprising a second fluid component, the second fluid component comprising:
• i) about 75-85% by weight or volume of at least one siloxane polymer;
• ii) about 1-20% by weight or volume of hydrogen peroxide;
• iii) about 0-25% by weight or volume of a surfactant;
• wherein the injecting comprises mixing the first and second fluid components within a mixing tip in the two-fluid component injection device to form an active hemostatic dressing, the active hemostatic dressing being injectable into the wound to form the soft solid artificial blockage within the wound,
• wherein the first fluid component and the second fluid component are kept separately within the two isolated chambers of the two-fluid injection device until mixed within the mixing tip for application into the wound,
• wherein the iron oxides in the mixture function as negative co-catalysts in the decomposition of hydrogen peroxide,
• wherein the siloxane polymer curing agent in the first fluid component is selected from the group consisting of platinum, tin, palladium, rhodium, and respective compounds, salts, complexes thereof, and a combination thereof,
• wherein the soft solid artificial blockage conforms to irregular wound surfaces, and the hydrogen peroxide in the soft solid artificial blockage is less than 5% by weight or volume;
• and
• allowing the composition to penetrate the wound or body cavity and expand therein to form a soft solid artificial blockage within the wound, and wherein the hydrogen peroxide in the soft solid artificial blockage is less than 5% by weight or volume.